KBI's PUREplatform™ is a game-changing microbial expression offering that redefines biopharmaceutical manufacturing.
The platform leverages the proprietary PUREcoli™ strain and cutting-edge screening packages for unmatched efficiencies and optimized production processes.
Hear from Aaron Pilling, Ph.D. and Senior Director of Process Development, as he discusses the KBI PUREplatform, a premium microbial cell line development (CLD) platform that delivers unmatched efficiencies for biopharmaceutical production.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com
